Variable name;level;Overall;NST;Lobular;Others;p;test
;n;1357;1265;54;36;;
Age;[0 -30);95;94 (98.9);1 (1.1);0 (0);0.005;
;[30 -35);246;236 (95.9);3 (1.2);7 (2.8);;
;[35 -40);460;432 (93.9);15 (3.3);13 (2.8);;
;40+;554;502 (90.8);35 (6.3);16 (2.9);;
Age (mean);;38.7 [34.9, 41.6];38.5 [34.8, 41.5];41.0 [39.4, 42.5];38.6 [35.9, 42.2];<0.001;nonnorm
Number of children;0;373;352 (94.6);9 (2.4);11 (3);0.007;
;1;279;263 (94.3);5 (1.8);11 (3.9);;
;More than 1;705;650 (92.3);40 (5.7);14 (2);;
BMI;<18.5;79;74 (93.7);2 (2.5);3 (3.8);0.876;
;25-29.9;257;241 (94.1);11 (4.3);4 (1.6);;
;>=30;107;99 (92.5);5 (4.7);3 (2.8);;
;18.5-24.9;807;750 (93.1);32 (4);24 (3);;
BMI (mean);;22.6 [20.5, 25.5];22.7 [20.5, 25.5];22.6 [20.8, 25.6];22.0 [20.0, 23.6];0.361;nonnorm
Treatment center;Curie Paris;818;764 (93.4);37 (4.5);17 (2.1);NaN;
;Curie St Cloud;538;501 (93.3);17 (3.2);19 (3.5);;
;Others;0;0 (NaN);0 (NaN);0 (NaN);;
Hereditary predisposition;No;547;523 (95.8);13 (2.4);10 (1.8);0.540;
;Yes;140;131 (93.6);5 (3.6);4 (2.9);;
Inflammatory BC;No;1338;1247 (93.3);54 (4);36 (2.7);0.523;
;Yes;18;18 (100);0 (0);0 (0);;
Clinical Tumor size (mm);;30.3 (21.7);30.3 (21.8);31.9 (20.2);27.7 (21.8);0.670;
Clinical N stage (TNM);N0;854;804 (94.3);30 (3.5);19 (2.2);0.602;
;N1;482;441 (91.5);24 (5);17 (3.5);;
;N2;7;7 (100);0 (0);0 (0);;
;N3;3;3 (100);0 (0);0 (0);;
SBR grade;Grade I;58;54 (93.1);3 (5.2);1 (1.7);<0.001;
;Grade II;528;476 (90.2);42 (8);10 (1.9);;
;Grade III;760;729 (95.9);9 (1.2);22 (2.9);;
Neoajuvant chemotherapy;No;744;666 (89.6);50 (6.7);27 (3.6);<0.001;
;Yes;612;599 (97.9);4 (0.7);9 (1.5);;
Chemotherapy setting;NAC;611;598 (97.9);4 (0.7);9 (1.5);NaN;
;Adjuvant;744;666 (89.6);50 (6.7);27 (3.6);;
;NAC and adjuvant;0;0 (NaN);0 (NaN);0 (NaN);;
;Chemotherapy without surgery;1;1 (100);0 (0);0 (0);;
;No;0;0 (NaN);0 (NaN);0 (NaN);;
Fertility preservation discussion;No;909;839 (92.4);46 (5.1);23 (2.5);0.014;
;Yes;447;426 (95.3);8 (1.8);13 (2.9);;
